TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Researchers studying older adults’ brain tissue found that faster cognitive decline was associated with fewer large nerve fibers, abnormal myelin and lower NRF2 levels in oligodendrocytes. Mouse experiments suggest that reducing NRF2 in those cells can cause similar changes, but whether medicines targeting the pathway can help prevent age-related decline remains unknown.
Researchers have linked lower NRF2 activity in oligodendrocytes—brain cells that maintain the insulating coating around nerve fibers—with faster cognitive decline in older adults. The study, published in Nature Medicine, also found similar nerve-fiber and myelin abnormalities after reducing NRF2 in mice, pointing to a possible biological target for future treatments, not a proven therapy for age-related decline.
The team, led by researchers from the University of Edinburgh and the UK Dementia Research Institute, studied participants in the Lothian Birth Cohort 1936. Their cognitive abilities had been tracked from childhood, with assessments between ages 70 and 82 covering memory, processing speed and spatial reasoning. Of 1,091 cohort members, 866 completed additional testing after age 70; the researchers reported that nearly all experienced some decline, though the pace varied.
In brain tissue collected after death from a subset of participants, greater decline over time was associated with fewer large nerve fibers and abnormal accumulation of myelin, the fatty coating that helps electrical signals travel along those fibers. The tissue findings were associated with the rate of decline, not simply a person’s test performance at one age. The study reports an association in the human samples, which cannot by itself establish that the cell changes caused the decline.
The researchers also found lower levels of NRF2 in oligodendrocytes among people with more severe decline. NRF2 regulates genes involved in cellular defense and function. In experiments, reducing NRF2 specifically in oligodendrocytes in mice led to excessive myelin, loss of large nerve fibers and reduced improvement on cognitive performance measures as the animals aged. The results support a possible causal role in the animal model, while leaving open how closely that process maps to human aging.
Why Myelin-Producing Cells Matter
Oligodendrocytes are generally understood as support cells: they produce and maintain myelin, which helps nerve cells communicate. The findings suggest that with age, problems in these cells may contribute to damage rather than simply reflect it. This adds a potential cellular mechanism for cognitive decline and may help researchers distinguish changes linked to gradual decline from measures of cognition taken at one point in time.
The work also identifies the NRF2 pathway as a possible treatment target. The source report notes that drugs acting on this pathway are already used for other neurological conditions, including multiple sclerosis, and that previous research has found cognitive benefits from increasing NRF2 activity in people with MS. That history makes the pathway relevant to investigate, but it does not show that those drugs prevent or treat age-related cognitive decline. Trials would need to establish safety and benefit for that specific purpose.
As an affiliate, we earn on qualifying purchases.
From Cohort Records to Mouse Tests
The human findings draw on the Lothian Birth Cohort 1936, whose participants have unusually long records of cognitive testing. Repeated assessments let researchers compare the pace of change across older adulthood, rather than relying only on a single late-life score. A subset of the participants later donated brain tissue for analysis, allowing the team to compare recorded cognitive trajectories with biological features observed after death.
The study combined that observational evidence with experiments in mice. Human tissue can reveal which brain changes are associated with decline, while controlled animal experiments can test whether changing a specific cell process produces related effects. Here, reducing NRF2 in oligodendrocytes produced abnormalities resembling those seen in the human samples. The two approaches strengthen the case for further study, but neither establishes that an NRF2-targeting medicine will preserve cognition in older people.
“As the prevalence of cognitive decline is rising with an aging population and no current treatments exist, we are excited about this work as it points to a potential strategy for new therapeutic strategies to preserve cognitive ability in aging.”
— Veronique Miron, MRC Senior Non-Clinical Fellow and UK Dementia Research Institute group leader at the University of Edinburgh and St. Michael’s Hospital, part of Unity Health Toronto
As an affiliate, we earn on qualifying purchases.
Limits of the Human Evidence
The human tissue results are associations: they show that lower oligodendrocyte NRF2 and myelin and nerve-fiber abnormalities tracked with faster cognitive decline, but do not establish the order or cause of those changes in people. The tissue came from a subset of cohort members and was examined after death. The source report does not provide enough detail here to assess how the findings apply across different populations or causes of cognitive impairment.
The mouse experiments offer evidence that lowering NRF2 can produce related effects in animals, but they do not prove that the same process explains decline in humans. It is also unclear whether increasing NRF2 in older people would reverse existing damage, slow future decline, or produce a meaningful benefit. No clinical trial of an NRF2-targeting treatment for age-related cognitive decline is reported in the material provided.
oligodendrocyte support supplements
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Testing NRF2 as a Treatment Target
The immediate next step is further research into how NRF2 affects oligodendrocytes and myelin as the brain ages, including whether the changes can be prevented or reversed. Researchers would also need to determine whether a drug that acts on the pathway reaches the relevant brain cells and can be used safely in older adults.
Any move toward repurposing existing medicines would require studies designed specifically for age-related cognitive decline, followed by clinical trials measuring cognitive outcomes and side effects. Until such evidence is available, the findings identify a candidate pathway for research; they do not support taking an existing neurological medicine to protect memory or thinking.
cognitive decline prevention supplements
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
What did the study find?
In older adults’ brain tissue, faster cognitive decline was associated with fewer large nerve fibers, abnormal myelin and lower NRF2 levels in oligodendrocytes. Reducing NRF2 in these cells in mice caused similar changes and affected cognitive performance measures.
What are oligodendrocytes and myelin?
Oligodendrocytes are brain cells that produce and maintain myelin, a coating around nerve fibers that helps electrical signals travel efficiently. The study suggests that dysfunction in these normally supportive cells may contribute to age-related brain changes.
Does this prove low NRF2 causes cognitive decline in people?
No. The human tissue findings show an association, not proof of cause. Mouse experiments support a possible causal role in that model, but further research is needed to establish what happens in people.
Could an existing drug prevent age-related cognitive decline?
The study points to the NRF2 pathway, which is targeted by medicines used for other conditions. The source report does not establish that those medicines prevent or treat age-related cognitive decline; that would require research and clinical trials in the relevant population.
Source: rss
Cold & flu season Picks
humidifiers
As an affiliate, we earn on qualifying purchases.
